Cemdisiran clinical trials
How each study uses cemdisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cemdisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 2
Regeneron Pharmaceuticals (7) · Alnylam Pharmaceuticals (3) · Austin Neuromuscular Center (1) · Mario Negri Institute for Pharmacological Research (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test cemdisiran.
- May 2027Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisEarly Phase 1 · Austin Neuromuscular Center
Studies
Open first, then newest update. How each study uses cemdisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyRecruitingPhase 3Regeneron PharmaceuticalsNCT06541704Written as Cemdisiran
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksRecruitingPhase 3Regeneron PharmaceuticalsNCT05744921Written as Cemdisiran
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRecruitingPhase 3Regeneron PharmaceuticalsNCT07154745Written as Cemdisiran
- Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisRecruitingEarly Phase 1Austin Neuromuscular CenterNCT06479863Written as Pozelimab/Cemdisiran
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05070858Written as Pozelimab + Cemdisiran
- Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab TherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04888507Written as Cemdisiran
- Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04811716Written as Cemdisiran
- A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)TerminatedPhase 2Alnylam PharmaceuticalsNCT03841448Written as Cemdisiran
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04601844Written as Cemdisiran
- Eculizumab to Cemdisiran Switch in aHUSWithdrawnPhase 2Mario Negri Institute for Pharmacological ResearchNCT03999840Written as cemdisiran
- A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNHCompletedPhase 1/2Alnylam PharmaceuticalsNCT02352493Written as ALN-CC5
- A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnPhase 2Alnylam PharmaceuticalsNCT03303313Written as Cemdisiran
Given beside what is tested · 3 — cemdisiran is usual care or a partner of the new treatment
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentCompletedPhase 3Regeneron PharmaceuticalsNCT05133531Written as Cemdisiran
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Cemdisiran
- A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04940364Written as Cemdisiran
Codes
What other systems call cemdisiran · ClinicalTrials.gg INT017860
- UNII (FDA) S66Z65E10TCEMDISIRANOne source FDA
- NCI Thesaurus C120319CemdisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S66Z65E10T | CEMDISIRAN | One source FDA |
| NCI Thesaurus | C120319 | Cemdisiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.